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MEssagE
Quantitative fluorescence endoscopy (QFE) is 
a new technique that can visualise and quan-
tify fluorescently tagged tumour tissue. In 25 
patients with locally advanced rectal cancer 
(LARC), we evaluated QFE targeting vascular 
endothelial growth factor A (VEGFA) to detect 
residual tumour after neoadjuvant chemora-
diotherapy (nCRT). QFE detected significantly 
higher fluorescence in tumour compared with 
normal rectal tissue and fibrosis, and improved 
prediction of final pathology results in 16% of 
patients compared with standard MRI and white-
light endoscopy. QFE is a promising technique to 
aid clinical response assessment in patients with 
LARC and warrants further validation in larger 
clinical trials.  ClinicalTrials. gov (NCT01972373).
IN MorE dETaIl
Patients with LARC receive nCRT followed by 
surgery to achieve local disease control. Interest-
ingly, 15%–27% of patients have a pathological 
complete response, that is, no residual cancer 
cells are found in the surgical specimen.1–3 There 
is an increasing interest in identifying patients 
with a clinical complete response before surgery, 
as non-operative management for these patients 
is associated with high survival rates, reduced 
morbidity and improved functional outcomes.4–8 
However, assessing tumour response after nCRT 
is challenging. White-light endoscopy provides 
only morphological information, while MRI 
cannot always distinguish viable tumour from 
fibrosis.9–11 QFE is a novel endoscopy tech-
nique that visualises and quantitatively measures 
the presence of targeted fluorescence tracers in 
tissue. We hypothesised that VEGFA-targeted 
QFE can be of additional value in restaging 
patients with LARC. In untreated patients, 
QFE showed clearly enhanced fluorescence in 
all rectal tumours compared with normal rectal 
tissue (figure 1A). The tumour-to-normal ratio 
of 3.1 (figure 1B) signifies QFE can be used to 
localise rectal cancer.
In this pilot study, we included 25 patients 
with LARC who were treated with nCRT (online 
supplementary table S1). QFE was performed 
at day of surgery, which enables comparison of 
QFE with standard clinical restaging (MRI and 
white-light endoscopy) and correlation to histo-
pathology of the surgical specimen (figure 2A).
In all patients, vital tumour tissue showed 
high fluorescence compared with normal rectal 
tissue or fibrosis (online supplementary figure 
S1). Fluorescence quantification confirmed that 
fluorescence of tumour tissue (n=155 measure-
ments) was higher than normal rectal tissue 
and fibrosis (n=100 measurements) (p<0.001) 
(figure 2B). The receiver operating character-
istic curve showed a fluorescence cut-off value 
of 2.00×10−2 (area under the curve 0.925) 
(figure 2C,D). QFE was true positive in 21 of 25 
patients as mucosal tumour (n=19, figure 3A) or 
even submucosal tumour (n=2, figure 3B) was 
confirmed by histology. QFE was truly negative 
in 2 of 25 patients, as histology confirmed patho-
logical complete response (ypT0N0) (figure 3C). 
QFE was false positive in 1 of 25 patients, who 
showed extensive polypoid tissue on white-light 
endoscopy with one apparent fluorescent spot, 
where histology showed no invasive tumour 
(ypT0N0), but instead one locus with high-grade 
dysplasia (figure 3D). In 1 of 25 patients, QFE 
was false negative, and histology showed micro-
scopic residual tumour: one locus situated in the 
submucosa.
Compared with standard clinical restaging, 
QFE would have changed the diagnosis in 4 of 25 
patients (16%) (online supplementary figure S2). 
Three patients, categorised as clinical complete 
responders by MRI and white-light endoscopy, 
showed fluorescence with QFE and indeed 
showed vital tumour at histopathological exam-
ination (n=2) or regrowth already after 2 months 
of watchful waiting (n=1). One patient was clin-
ically categorised as having residual tumour, but 
QFE showed low fluorescence and pathological 
examination confirmed a pathological complete 
response.
In our small sample size of 25 patients, the 
initial positive predictive value was 95% for QFE 
compared with 87.5% for MRI and 90% for 
white-light endoscopy. The accuracy of QFE was 
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Figure 1 (A) Representative fluorescence images of the quantitative fluorescence endoscopy (QFE) procedure in untreated rectal cancer. From 
left to right: a high-definition white-light video endoscope image; a white-light image from the QFE fibreoptic, followed by the corresponding near-
infrared (NIR) fluorescence image captured with an exposure time of 100 ms and the composite image of both modalities. The maximum quantified 
fluorescence value is depicted on the NIR fluorescence image. The rightmost image shows the HE staining of a forceps biopsy of the fluorescent area, 
confirming adenocarcinoma. (B) Fluorescence quantification results in 10 untreated patients. Tumour tissue shows higher fluorescence compared with 
normal rectal tissue. Boxplot centreline is at median, the bounds of the box at 25th to 75th percentiles, the whiskers depict the minimum–maximum.
92% compared with 84% for MRI and 80% for white-light 
endoscopy.
Find more details on online supplementary methods and 
results.
CoMMENTs
This is the first-in-human study demonstrating that in vivo 
VEGFA-targeted QFE can improve the response assessment of 
patients with LARC after nCRT. We observed a sensitivity of 
95% and accuracy of 92% for QFE compared with the reported 
respectively 71% and 89% of MRI combined with white-
light endoscopy.10 The addition of QFE to MRI and white-
light endoscopy resulted in more accurate clinical restaging 
in 16% of patients. Moreover, QFE is easy to perform during 
white-light endoscopy: the imaging and spectroscopy probes 
can be inserted in the working channel of any clinical video 
endoscope, the QFE measurements are operator independent 
and the procedure takes slightly more time (5–10 min). Impor-
tantly, no tracer-related or procedure-related adverse events 
were observed in this study.
When QFE is applied for restaging purposes, fluorescence 
quantification is important. Wide-field fluorescence visualisa-
tion alone does not necessarily reflect true tracer accumulation 
as fluorescence is influenced by tissue optical properties and 
could therefore lead to incorrect recommendations in clinical 
practice. By quantifying the fluorescence with multi-diameter 
single fibre reflection/single fibre fluorescence (MDSFR/SFF) 
spectroscopy, the fluorescence signals are corrected for tissue 
optical properties like scattering and absorption, circum-
venting this problem.12 13
Recent follow-up data showed that 19% of patients in 
watchful waiting, experience early tumour regrowth within 
12 months.14 The majority of these patients had ypT3 or 
ypT4 disease at salvage, suggesting the presence of residual 
disease, intraluminal and also in deeper layers of the rectum. 
QFE might improve identification of these patients, as in this 
study QFE measured increased fluorescence in two of three 
patients with only submucosal tumour, that is, no tumour 
reaching the rectal mucosa. We hypothesise that bevacizum-
ab-800CW could accumulate at the mucosal side because the 
tumour microenvironment was not yet normalised after nCRT, 
with still increased levels of VEGFA. A tracer that accumulates 
in the microenvironment could therefore offer an advantage 
for restaging compared with tracers that target proteins on 
tumour cell membranes. In addition, bevacizumab-800CW 
is a near-infrared tracer allowing deeper tissue penetration 
compared with tracers in the visible spectrum.
In this pilot study, QFE was false positive in one patient who 
turned out to have one locus of high-grade dysplasia at the 
rectal lumen. This is not surprising as a former study showed 
that bevacizumab-800CW also accumulates in low-grade and 
high-grade dysplastic adenomas which hampers discrimina-
tion between dysplasia and cancer.13 QFE was false negative in 
one patient who had one microscopic tumour locus present in 
the submucosa. Possibly, raising the tracer dose could provide 
stronger fluorescence signals and thus improve QFE detec-
tion. A clinical dose-finding study using bevacizumab-800CW 
for detection of colorectal adenomas reported that a higher 
tracer dose of 25 mg increased the target-to-background ratio 
almost twofold.13 Potentially, future complementary detection 
systems such as optoacoustic imaging, which combines the 
rich contrast of optical imaging with the higher penetration 
of radiofrequency waves, may further improve submucosal 
evaluation.
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Figure 2 (A) Schematic overview of the clinical and study procedures. 4.5 mg bevacizumab-800CW was intravenously administered 2–3 days 
prior to quantitative fluorescence endoscopy (QFE). QFE consisted of wide-field fluorescence imaging, followed by fluorescence quantification using 
MDSFR/SFF spectroscopy and taking four forceps biopsies of normal rectal tissue (10 cm proximal from the tumour) and of 4 areas of the rectal 
tumour when present. (B) Fluorescence quantification results of the QFE procedures after neoadjuvant chemoradiotherapy (nCRT), depicted per tissue 
type. Tumour tissue shows higher fluorescence compared with fibrosis and normal tissue. Negative control tissue (of measurements of tumour and 
normal rectal tissue from a patient without tracer) showed no detectable fluorescence, signifying the measured fluorescence originated from the 
tracer. Boxplot centreline is at median, the bounds of the box at 25th to 75th percentiles, the whiskers depict the minimum–maximum. **p≤0.01; 
***p≤0.001, one-way ANOVA test with Tukey post hoc analysis. (C) The receiver operating characteristic curve of quantified fluorescence of normal 
rectal tissue (n=100 measurements) vs tumour tissue (n=115 measurements) shows an area under the curve of 0.925. Normal rectal tissue included 
normal rectal tissue measurements of all patients and fibrosis measurements of pathological complete response. Tumour tissue included all lesion 
measurements of all patients with residual tumour at pathological examination. (D) Contingency table. HGD, high-grade dysplasia.
Our study has some limitations. We found a relatively low 
specificity and negative predictive value of QFE (67%) in this 
feasibility study, which might be due to the relatively small 
sample size. Next to this, the included patients were referred 
to our tertiary centre and represent patients with relatively 
complex LARC with extensive tumour (T4 in 40%) and high 
nodal stage (N2 in 64%) compared with the patients with 
relatively uncomplex LARC in standard practice. This also 
resulted in a relatively small portion of patients who expe-
rienced a pathological complete response (12%), compared 
with 15%–27% pathological complete response described in 
the literature.1 2
In conclusion, the results of this pilot study, even in this 
small group of patients, are encouraging and are poten-
tially a first step towards quantitative fluorescence endos-
copy for tumour response evaluation following neoadjuvant 
treatment. Ultimately, the combination of MRI, white-light 
endoscopy and QFE may prove to be the strategy to eval-
uate individual patient response and guide clinical deci-
sion-making. To realise this strategy, the capability of QFE in 
clinical response evaluation in patients with LARC, including 
determination of a definitive cut-off value that discriminates 
tumour from normal tissue, needs further evaluation in a 
larger prospective cohort.
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Figure 3 (A–D) Representative images of the quantitative fluorescence endoscopy (QFE) procedure after neoadjuvant chemoradiotherapy of a 
patient with (A) residual tumour, (B) submucosal tumour, (C) mucosal high-grade dysplasia (HGD) and (D) a pathological complete response. From 
left to right: a high-definition white-light video endoscope image of the rectal tumour; a white-light image from the QFE fibreoptic, followed by 
the corresponding near-infrared (NIR) fluorescence image captured with an exposure time of 100 ms and the composite image of both modalities. 
The maximum quantified fluorescence value is depicted on the NIR fluorescence image. The rightmost column depicts an HE staining of the surgical 
specimen in which the pathological TNM stage is indicated.
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